Sociodemographic and clinical characteristics and treatments of patients before initiating GLP-1Ra treatment
| Age, years, mean (SD) | 58.32 (10.4) |
| Sex, male, N (%) | 198 (49.1) |
| Weight, kg, mean (SD) | 97.59 (17.9) |
| Height, cm, mean (SD) | 164.0 (10.0) |
| BMI, kg/m2, mean (SD) | 36.22 (5.5) |
| Normal 18.5–25, N (%) | 1 (0.2) |
| Overweight 25–30, N (%) | 24 (6.0) |
| Obese ≥30, N (%) | 378 (93.8) |
| Waist size, cm, mean (SD) | 114.28 (15.0) |
| Systolic/diastolic blood pressure, mm Hg, mean (SD) | 140.55 (18.0)/80.35 (10.0) |
| Smoking habit, N (%) | |
| Current | 55 (13.6) |
| Former | 136 (33.7) |
| Never smoked | 212 (52.6) |
| Glycaemic control | |
| Fasting blood glucose, g/L, mean (SD) | 1.77 (0.6) |
| HbA1c %, mean (SD) | 8.41 (1.4) |
| HbA1c<6.5%, N (%) | 24 (6.0) |
| HbA1c 6.5–7%, N (%) | 33 (8.2) |
| HbA1c 7–8%, N (%) | 130 (32.3) |
| HbA1c>8%, N (%) | 216 (53.6) |
| Lipid parameters, mean (SD) | |
| Total cholesterol (g/L) | 1.8 (0.4) |
| HDL cholesterol (g/L) | 0.43 (0.1) |
| LDL cholesterol (g/L) | 1.01 (0.3) |
| Triglycerides (g/L) | 1.95 (1.4) |
| Creatinine clearance, mL/min, mean (SD) | 88.9 (24.1) |
| Normal ≥90, N (%) | 160 (46.8) |
| Mild renal impairment 60–90, N (%) | 145 (42.4) |
| Moderate renal impairment 45–60, N (%) | 30 (8.8) |
| Moderate renal impairment 30–45, N (%) | 7 (2.0) |
| DM2 history | |
| Time since diagnosis (years), mean (SD) | 9.91 (7.0) |
| Age at diagnosis (years), mean (SD) | 48.35 (10.3) |
| Time between DM2 diagnosis and first treatment, N (%) | |
| Concomitant | 261 (81.1) |
| 1 year | 18 (5.6) |
| 1–5 years | 31 (9.6) |
| >5 years | 12 (3.7) |
| Antidiabetic treatment before/after initiation of GLP-1Ra | |
| OAD only, N (%) | 217 (53.8)/223 (55.3) |
| OAD only, 1 drug, N (%) | 76 (35.0)/0 |
| OAD only, 2 drugs, N (%) | 83 (38.2)/145 (65.0) |
| OAD only, 3 drugs, N (%) | 52 (24.0)/71 (31.8) |
| OAD only, ≥4 drugs, N (%) | 6 (2.8)/7 (3.1) |
| Insulin only, N (%) | 21 (5.2)/29 (7.2) |
| OAD+insulin, N (%) | 161 (40.0)/146 (36.2) |
| No antidiabetic drugs, N (%) | 4 (1.0)/5 (1.2) |
BMI, body mass index; DM2, type 2 diabetes mellitus; GLP-1Ra, glucagon-like peptide-1 receptor agonists; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OAD, oral antidiabetic drug.